StockNews.AI

Rapid Micro Biosystems Announces Record Preliminary Unaudited Fourth Quarter and Full Year 2025 Revenue

StockNews.AI • 4 hours

MMSAGNBMY
High Materiality8/10

Information

LEXINGTON, Mass., Jan. 13, 2026 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the...

Original source

AI Summary

Rapid Micro Biosystems anticipates a record fourth quarter revenue growth of 37%, driven by increased demand and significant orders from major clients. The company is well-positioned for continued growth in 2026, supported by strong performance in its Growth Direct systems, further validating its market presence.

Sentiment Rationale

Strong revenue forecasts and record orders suggest robust demand and positive market sentiment, reminiscent of previous earnings surprises that propelled stock prices upward.

Trading Thesis

RPID is poised for short-term gains driven by strong revenue growth and market validation.

Market-Moving

  • Upcoming J.P. Morgan Healthcare Conference may boost visibility and investor interest.
  • Q4 results exceeding guidance may lead to positive stock momentum.
  • Record multi-system orders confirm strong customer demand for RPID's products.
  • Increase in recurring revenue indicates stability and growth potential.

Key Facts

  • RPID expects Q4 2025 revenue of $11.3 million, up 37%.
  • Company received record orders from a top 20 biopharma client.
  • 2025 total revenue projected at $33.6 million, a 20% increase.
  • Growth Direct systems placements surge; 16 installed in Q4 2025.
  • Upcoming presentation at J.P. Morgan Healthcare Conference on January 15.

Companies Mentioned

  • MilliporeSigma (Not applicable): Strategic partnership may enhance RPID's growth and market reach.
  • Top 20 global biopharma customer (Not applicable): Significant orders validate RPID's position as a key supplier.

Corporate Developments

This falls under 'Corporate Developments' as RPID reports significant revenue growth and new client orders, indicative of its strong market demand and operational efficacy in the life sciences sector.

Rapid Micro Biosystems Reports Record Revenue for Fourth Quarter and Full Year 2025

LEXINGTON, Mass., Jan. 13, 2026 (GLOBE NEWSWIRE) — Rapid Micro Biosystems, Inc. (Nasdaq: RPID), a leader in life sciences technology, has announced its preliminary unaudited revenue results for the fourth quarter and full year 2025. The company is set to report approximately $11.3 million in revenue for Q4 2025, marking a significant growth of about 37% compared to the same period last year. Furthermore, the full-year revenue is expected to be around $33.6 million, reflecting a growth of approximately 20% year-over-year.

Fourth Quarter Highlights

In Q4 2025, Rapid Micro Biosystems anticipates that its recurring revenue will reach approximately $4.6 million, a growth of roughly 10% compared to Q4 2024. This quarter saw the company secure a record order of 16 new Growth Direct systems from a top global biopharma client, enhancing the automation of their global manufacturing network.

  • Expected Q4 2025 revenue: $11.3 million
  • Q4 recurring revenue: $4.6 million
  • Number of new Growth Direct systems placed: 16
  • Customer systems validated in Q4: 3

Full Year 2025 Overview

For the full year 2025, Rapid Micro expects to achieve approximately $33.6 million in total revenue, supported by a 15% increase in recurring revenue, anticipated to be about $17.8 million. The annual growth is attributed to the placement of 28 new Growth Direct systems and the successful validation of 18 customer systems throughout the year. The cumulative total now stands at 190 systems placed globally, with 155 systems having completed validation.

  • Expected full year 2025 revenue: $33.6 million
  • Expected full-year recurring revenue: $17.8 million
  • Total Growth Direct systems placed in 2025: 28
  • Cumulative systems validated: 155

CEO Insights and Future Outlook

“We are pleased to report record results for the fourth quarter that exceeded our raised guidance issued in November,” stated Robert Spignesi, President and CEO of Rapid Micro Biosystems. “This broad-based strength across systems, consumables, and services position us well for continued growth moving into 2026.”

Looking ahead, the company emphasizes its commitment to driving further advancements and strategic partnerships, including its ongoing collaboration with MilliporeSigma.

Upcoming Presentation and Financial Results Announcement

The company plans to release complete financial results for both the fourth quarter and full year 2025 in early 2026. In addition, Rapid Micro will present at the 44th Annual J.P. Morgan Healthcare Conference on January 15, 2026, at 2:15 p.m. ET. The webcast of this event will be available on the Rapid Micro investor relations website and will be archived for 30 days for those unable to attend live.

For continued updates, stakeholders are encouraged to check the company’s investor relations page at Rapid Micro Investor Relations.

About Rapid Micro Biosystems

Rapid Micro Biosystems is dedicated to providing critical automation solutions for the manufacturing and release of healthcare products, such as biologics and vaccines. Its flagship Growth Direct system enhances efficiency in microbial quality control testing, ensuring rapid and reliable results essential for the pharmaceutical industry. For more information, visit www.rapidmicrobio.com.

Related News